KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $147.0 million.

  • Gilead Sciences' Capital Expenditures rose 425.53% to $147.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.0 million, marking a year-over-year decrease of 1455.16%. This contributed to the annual value of $523.0 million for FY2024, which is 1059.83% down from last year.
  • Latest data reveals that Gilead Sciences reported Capital Expenditures of $147.0 million as of Q3 2025, which was up 425.53% from $107.0 million recorded in Q2 2025.
  • Gilead Sciences' 5-year Capital Expenditures high stood at $247.0 million for Q1 2022, and its period low was $104.0 million during Q1 2025.
  • In the last 5 years, Gilead Sciences' Capital Expenditures had a median value of $141.0 million in 2024 and averaged $145.9 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 4969.7% in 2022, then plummeted by 5587.04% in 2023.
  • Over the past 5 years, Gilead Sciences' Capital Expenditures (Quarter) stood at $156.0 million in 2021, then increased by 16.03% to $181.0 million in 2022, then rose by 18.78% to $215.0 million in 2023, then crashed by 31.63% to $147.0 million in 2024, then changed by 0.0% to $147.0 million in 2025.
  • Its Capital Expenditures stands at $147.0 million for Q3 2025, versus $107.0 million for Q2 2025 and $104.0 million for Q1 2025.